Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers

Sponsor
Shaare Zedek Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT00434772
Collaborator
(none)
1
17

Study Details

Study Description

Brief Summary

Thesis Infants of diabetic mothers are at high risk to develop hypoglycemia after birth.

After birth, glucose and ketone bodies are the main substrates of brain energy. Under normal condition, the adrenergic response seen immediately after birth suppresses insulin release and stimulates glucagon secretion which enhances gluconeogenesis and ketogenesis.

An inversion of the insulin/glucagon ratio is seen soon after birth as a normal, physiologic phenomenon. Consequently, a post delivery glucose nadir is reached between 30 to 90 minutes after birth, followed by a spontaneous recovery before 3-4 hours of age.

In infants of diabetic mothers, this inversion of the ratio is postponed and a more profound and sustained hypoglycemia is seen.

Early feeding is of great importance to diminish the severity and incidence of hypoglycemia. But, if despite an appropriate calorie intake, low levels of sugar are seen, an intravenous infusion of glucose should be commenced. In case that IV glucose is not effective or can't be supplied immediately, intramuscular glucagon is a therapeutic alternative.

We hypothesize that a single intramuscular injection of glucagon together with the appropriate oral intake of nutrients is a safe and an effective alternative to the IV infusion of glucose alone in the treatment of hypoglycemia in term infants of diabetic mothers.

Methods Appropriately grown or large for date, term infants of insulin treated diabetic mothers, with no other known medical problems, are potential candidates for our study.

Hypoglycemia will be defined as serum glucose level lower than 45 mg%. Infants of diabetic mothers will arrive to the nursery and immediately receive early feeding before 30 minutes of life. At that time, glucose will be checked. If glucose level is lower than 45 mg%, treatment with IV glucose or IM glucagon will be initiated. Glucose will be checked every hour for 4 hours and then every 3 hours (before each meal) for the next 20 hours.

In case blood glucose level is lower than 20 mg% or falls below 45 mg% despite glucagon treatment, IV glucose will immediately be instituted.

Our aim is to check that IM Glucagon is as good as IV glucose in the treatment of hypoglycemia in infants of diabetic mothers. We will compare glucose levels after treatment with IV glucose and IM glucagon, the time till normalization of glucose and full feeding is achieved and the number of hospitalization days in both groups.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers
Study Start Date :
Dec 1, 2007
Actual Primary Completion Date :
May 1, 2009
Actual Study Completion Date :
May 1, 2009

Outcome Measures

Primary Outcome Measures

  1. glucose []

Secondary Outcome Measures

  1. hospitalisation days []

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 48 Hours
Sexes Eligible for Study:
All
Inclusion Criteria:
  • asymptomatic hypoglycemia

  • infant of insulin treated diabetic mother

  • AGA or LGA

  • no other known medical problems

Exclusion Criteria:
  • concurrent medical problems

  • symptomatic hypoglycemia

  • glucose under 20 mg%

Contacts and Locations

Locations

Site City State Country Postal Code
1 Share Zedek Medical Center Jerusalem Israel 91031

Sponsors and Collaborators

  • Shaare Zedek Medical Center

Investigators

  • Principal Investigator: Bisseliches Myriam, MD, Shaare Zedek Medical Center - Jerusalem - Israel

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00434772
Other Study ID Numbers:
  • bisseliches-glucagon-ctil
First Posted:
Feb 13, 2007
Last Update Posted:
May 28, 2009
Last Verified:
May 1, 2009
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 28, 2009